Unlock the Future of Cancer Research with OrganoidXplore™
Crown Bioscience’s Organoid Panel Screening Service

Why wait for others to catch up when you can be at the forefront of innovation?
Pioneer Cancer Research

Access cutting-edge organoid panel screens with translatable results.

- Fast-track your oncology drug development with results from 50 models in just 6 weeks.
- Identify your lead compound(s), stratify patients into responders, partial responders, and non-responders or preselect models for follow up studies \textit{in vitro}/\textit{in vivo}.

**Leverage Unparalleled Model Diversity**

Quantify efficacy across organoids with specific mutations and diverse genetic backgrounds.

- Measure tumor drug response in both tumor and normal organoids
- Explore new indications with validated targets
- Benefit from inclusion of 9 normal models, including 6 matched normal/disease pairs for comprehensive analysis
- Access 50 well-characterized PDO and PDXO models for enhanced precision
- Representing clinically relevant mutational profiles, including KRAS, BRAF, BRCA 1 and 2, and EGFR

**Embrace Reliable Data**

Rely on rigorous validation and quality assurance procedures to ensure the accuracy and trustworthiness of your data.

- Organoid quality assurance: SNP verified and mycoplasma tested
- Quantify cell viability and explore potential drug combinations
- Well characterized against 4 standard of care agents (Cisplatin, Gemcitabine, Paclitaxel, and AMG510)
- Assay performance validated by inclusion of chemotherapeutic agent and vehicle controls on each plate

**Choose The Panel That Best Suits Your Needs**

Explore new indications and test efficacy in our OrganoidXplore™ panels.

**OrganoidXplore Full Panel Composition**

- Colorectal models
- Lung models
- Pancreatic models
- Breast models
- Ovarian models
- Cervical models
- Melanoma models

- Normal
- Cancer

**OrganoidXplore KRAS Panel Composition**

- Colorectal models
- Lung models
- Pancreatic models
- Ovarian models

- WT
- G12C
- G12D
- G12V
- G12S
- G13D
- Q61H

**Full Panel**

- 50 models
- 7 indications

**KRAS Panel**

- 25 models
- 4 indications

RNA seq, WES and SoC data available
Most models available as PDX for follow up studies
Ensure accuracy and reproducibility across runs with a semi automated workflow that uses liquid handlers.

- Agents tested at 9 concentrations on the preferred panel
- 5-day incubation time with compounds for timely results
- Benefit from vehicle and reference controls for reliable comparisons
- Optional: conduct drug combination studies for enhanced therapeutic potential
- Receive a comprehensive customer report containing 9-point dose-response curve graphs, IC50s, study design and control performance